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The antiangiogenic effects of thalidomide have been assessed in clinical trials in patients with various solid and haematological
malignancies. Thalidomide blocks the activity of angiogenic agents including bFGF, VEGF and IL-6. We undertook an open-label study
using thalidomide 100mg once daily for up to 6 months in 20 men with androgen-independent prostate cancer. The mean time of
study was 109 days (median 107, range 4–184 days). Patients underwent regular measurement of prostate-specific antigen (PSA),
urea and electrolytes, serum bFGF and VEGF. Three men (15%) showed a decline in serum PSA of at least 50%, sustained throughout
treatment. Of 16 men treated for at least 2 months, six (37.5%) showed a fall in absolute PSA by a median of 48%. Increasing levels of
serum bFGF and VEGF were associated with progressive disease; five of six men who demonstrated a fall in PSA also showed a
decline in bFGF and VEGF levels, and three of four men with a rising PSA showed an increase in both growth factors. Adverse effects
included constipation, morning drowsiness, dizziness and rash, and resulted in withdrawal from the study by three men. Evidence of
peripheral sensory neuropathy was found in nine of 13 men before treatment. In the seven men who completed six months on
thalidomide, subclinical evidence of peripheral neuropathy was found in four before treatment, but in all seven at repeat testing. The
findings indicate that thalidomide may be an option for patients who have failed other forms of therapy, provided close follow-up is
maintained for development of peripheral neuropathy.
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Prostate cancer is the second leading cause of cancer deaths in men
and curative therapy in the form of radical surgery or radiotherapy
is limited to patients with organ-confined disease. Endocrine
treatment by androgen ablation is a palliative measure for patients
with locally advanced or metastatic prostate cancer, but the
response to endocrine therapy is temporary, usually in the range
18–24 months, as castration appears to favour a subpopulation of
cells that seem to thrive in the absence of androgens (Logothetis
et al, 1994). This property is thought to be dependent on the
autocrine or paracrine effects of growth factors, acting either
directly on the tumour cells, or indirectly on new blood vessel
formation (angiogenesis). Many agents have been tested with the
aim of improving the outlook in hormone-refractory disease, with
clinical response in terms of serum prostate-specific antigen (PSA)
levels and tumour mass observed in a minority. No regimen has
been found to provide a substantial improvement in survival time
and, importantly, many are detrimental to quality of life.
Thalidomide is a sedative, anti-inflammatory and immunosup-
pressive agent, which has been used or proposed for use in various
serious illnesses, including AIDS- and cancer-related cachexia,
leprosy and multiple sclerosis. Several clinical trials have employed
thalidomide in refractory malignancy with varying degrees of
success. In vitro data suggests that thalidomide has anti-
angiogenic activity, blocking the expression of multiple angiogenic
agents (D’Amato et al, 1994). Accordingly, an open-label phase II
study of thalidomide at a dose of 100mg daily in androgen-
independent prostate cancer was conducted to evaluate its efficacy
and tolerability. During the same period, Figg et al investigated the
use of thalidomide in patients with androgen-independent prostate
cancer at higher doses (daily doses of 200mg up to 1200mg), with
greater overall benefit observed in the low-dose arm.
MATERIAL AND METHODS
Patient characteristics
The main inclusion criterion for entry to the trial was a rising
serum PSA after initial response to hormonal manipulation
therapy. All patients had histological confirmation of prostate
adenocarcinoma and were managed at initial diagnosis by primary
androgen ablation with LHRH agonist injections or bilateral
subcapsular orchidectomy. Androgen-independence was defined
as a rising PSA value of at least 20ngml
 1 on two consecutive
occasions after the nadir of response to androgen ablation therapy,
or a rise of at least 5ngml
 1 if the absolute PSA value was less than
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 1. Thus all patients had progressive disease on biochem-
ical criteria (Bubley et al, 1999). Exclusion criteria included any
unstable medical condition, long-term corticosteroid therapy,
surgery or radiotherapy in the preceding 28 days, spinal cord
compression or severe bone pain requiring immediate treatment.
No patient had previously received chemotherapy for their
prostate cancer.
Study design
Thalidomide (Sauramide, Penn Pharmaceuticals, Tredegar, UK)
100mg was given once daily at bedtime for up to 6 months in an
open-label phase II study. All patients continued on prior hormone
therapy, except for the discontinuation of antiandrogen medica-
tion with a 1 month washout period.
Patients were assessed monthly to detect symptomatic adverse
drug reactions. Serum PSA, urea and electrolytes, liver function
tests and haematology were determined each month. Samples for
measurement of cytokine levels were processed within 1h and
serum stored at  201C until used for ELISA for bFGF/FGF2 and
VEGF, according to the manufacturer’s instructions (R&D, UK).
Lower urinary tract symptoms were assessed with the ICS male
questionnaire and performance status with the Medical Outcomes
Study Short Form 36 (SF 36) questionnaire (Ware et al, 1993) every
3 months. Nerve conduction studies (NCS) were undertaken at
screening and after 6 months, using bilateral lower limb recording
of the response amplitude and conduction velocity from two
sensory (sural and superficial peroneal) and two motor (common
peroneal and posterior tibial) nerves (Johnsen and Fuglsang-
Fredericksen, 2000). All of the sensory nerve action potential
(SNAP) data were pooled for analysis.
The protocol was approved by the Newcastle and North
Tyneside Health Authority Joint Ethics Committee, with written
informed consent from each subject.
Response evaluation
The primary end point of the study was the assessment of changes
in PSA based on the intention to treat. Decline in absolute PSA
value was defined as a reduction compared with the screening
value, which was maintained for at least 4 weeks. Patients showing
a decline in serum PSA of at least 50% without clinical evidence of
progression were considered to show a PSA response, according to
the guidelines of the Prostate-Specific Antigen Working Group
(Bubley et al, 1999). In addition, PSA velocity was recorded,
derived from the gradient of log plots of the PSA against time,
prior to and following initiation of thalidomide. Secondary end
points were evaluation of toxicity, tolerability and alterations in
levels of circulating growth factors.
Statistical analysis
Paired and unpaired t-tests were used for parametric data and the
Mann–Whitney U-test for nonparametric data, with statistical
significance inferred at Po0.05.
RESULTS
A total of 20 men were recruited (Table 1) and mean time on study
was 109 days (median 107, range 4–184 days). Reasons for
withdrawal were clinical progression resulting in bone pain (5) or
ureteric obstruction (2), adverse drug effects (3), colonic perfora-
tion (1), inability to comply with frequent hospital visits (1) and
withdrawal of consent (1) (demographic data given in Table 2). At
screening, the seven men who showed clinical progression on
thalidomide did not differ significantly from the study group
overall in respect of age, histological grade or performance status,
but the PSA was higher (median 322 vs 95ngml
 1, P¼0.06).
Subjects were followed up for a median of 13 months after
discontinuing thalidomide (mean 12, range 5–16 months). Nine
men had died at a median of 2 months following treatment (mean
3.7, range 0–10 months).
Prostate-specific antigen response
Prostate-specific antigen data are set out in Table 3 and values for
the seven men who completed the full 6 month study period
(patient numbers 1, 4, 7, 8, 11, 14 and 20) are illustrated in Figure 1.
Three of these seven (numbers 4, 7 and 20) showed a fall in
absolute PSA by a mean of 50% (range 24–77%), the PSA falling
over the study period and rising after discontinuation of the drug
in each case. The remaining four men did not show a fall in PSA.
Prostate-specific agent data were available for a further nine men
receiving treatment for at least 2 months. In this group, the PSA
fell in three by a mean of 46% (range 32–62%). One patient
showed an initial fall of 11% in the first month, but the PSA rose
above screening levels thereafter. Four men did not receive
thalidomide for 2 months, so their PSA data could not be
analysed. Overall, six out of the 16 men receiving thalidomide for
at least 2 months (37.5%) showed a fall in their serum PSA levels
by a mean of 48% (median 48%). Of these, three (18.8%) showed a
fall in PSA of at least 50%, representing 15% of the 20 patients
initially recruited with the intention to treat. Absolute PSA level,
PSA velocity, performance status, Gleason score and presence of
bone metastases did not influence the likelihood of PSA response.
Serum growth factor levels
Changes in serum bFGF and VEGF over the initial 3-month period
were evaluated in 11 patients. Overall, bFGF rose from
2.472.6pgml
 1 to 6.375.8 (mean7s.d.), and VEGF rose from
262.47215.4 to 337.57333.9pgml
 1. Subgroup analysis according
to PSA response showed concurrent changes in serum growth
factor levels and PSA (Figure 2). Five out of six men manifesting a
fall in PSA (‘group 1’) showed a decline in mean values for both
bFGF and VEGF to 0.670.93 and 151.5775.2pgml
 1 at the third
Table 1 Characteristics of recruited patients
Characteristic
Mean age (range) 71.1 (60–83) years
Mean pretreatment PSA (range) 305 (14–3302)ngml
 1
Gleason score for histology (range) 7.9 (6–10)
Local stage (T3/T4) 12/8
Bony metastases present 13 (65%)
Concurrent LHRH analogue therapy 14 (70%)
Previous bilateral subcapsular orchidectomy 6 (30%)
Table 2 Characteristics of men failing to complete the study
Characteristic
Time on study; mean (median) 69 (61) days
Mean age (range) 72.5 (60–83)
Mean pretreatment PSA (range) 451 (56–3302)ngml
 1
Gleason score for histology (range) 8.4 (7–10)
Local stage (T3/T4) 7/6
Bony metastases present 9 (69%)
Concurrent LHRH analogue therapy 8 (61%)
Previous bilateral subcapsular orchidectomy 5 (38%)
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lmonth, respectively. A slight rise in serum PSA in the third month
in this group coincided with a rise in VEGF, while the bFGF
continued to fall. Conversely, three out of four patients with a
rising PSA (‘group 2’) showed an increase in levels of both bFGF
(22.1734.3pgml
 1) and VEGF (521.07353.4pgml
 1). The differ-
ence between subgroups after treatment showed statistical
significance for bFGF (P¼0.04) but not VEGF (P¼0.18). One
patient who did not clearly fall into either group in terms of PSA
changes showed a rise in bFGF and a fall in VEGF.
Toxicity
Adverse drug effects are listed in Table 4. Constipation usually
responded to dietary advice and mild oral aperients, but one
patient with a past history of diverticular disease withdrew from
the study on developing peritonitis following perforation of a
colonic diverticulum. This man did not have rectal stenosis
because of his prostatic adenocarcinoma and constipation
associated with thalidomide was possibly a contributory factor.
‘Sedation hangover’, defined as drowsiness for several hours after
rising, was reported by three people. One person developed a
transient morbiliform rash after taking the drug for several weeks,
which affected the forearms and legs and resolved over a 2-week
period. Another patient with no past history of cerebrovascular
Table 3 Prostate-specific antigen data
Patient
Screening
PSA (ngml
 1) PSA nadir (ngml
 1) % PSA decline
a
Pretrial PSA vel.
(ngml
 1 month
 1)
Trial PSA vel.
(ngml
 1 month
 1)
1
b 87 DNF F 19 (22%) 9 (10%)
2 111 DNF F 31 (28%) 4 (4%)
3 3302 1256 62 514 (16%)  2046 ( 62%)
4
b 152 35 77 27 (18%)  19 ( 13%)
5 322 178 45 20 (6%)  104 ( 32%)
6 170 170 0 8 (5%)  4 (2%)
7
b 86 65 24 17 (20%)  14 ( 16%)
8
b 46 DNF F 5 (11%) 1 (2%)
9 56 50 11 25 (45%)  6(  11%)
10 69 NA F NA NA
11
b 74 DNF F 8 (11%) 7 (9%)
12 585 399 32 244 (42%)  132 ( 23%)
13 102 DNF F 15 (15%) 16 (16%)
14
b 25 DNF F 13 (52%) 2 (8%)
15 81 DNF F 8 (10%) 11 (14%)
16 143 140 2 4 (3%)  20 ( 14%)
17 65 NA F 18 (28%) NA
18 400 NA F 133 (33%) NA
19 400 NA F 43 (11%) NA
20
b 14 7 50 3 (21%)  5(  36%)
aBetween screening PSA and nadir.
bPatients completing full 6 months on thalidomide. DNF=did not fall. NA=not applicable.
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Figure 1 Prostate-specific antigen data for seven men completing 6
months on low-dose thalidomide. Prostate specific antigen values are
shown for the study period and the preceding 12 months. For the three
men showing a fall in PSA in response to thalidomide (patient numbers 4, 7
and 20, filled icons), values for the period up to 6 months after completion
of the study are also illustrated. Scr¼screening, ‘End’ refers to completion
of the trial.
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Figure 2 Prostate-specific antigen and growth factor changes. Changes
in mean serum PSA, bFGF and VEGF during the first 3 months of taking
thalidomide for men showing a decline (‘group 1’, closed icons, n¼6) or a
rise (‘group 2’, open icons, n¼4) in PSA. Values for each marker are
normalised to a value of 1 at screening and plotted on a logarithmic scale.
Error bars represent one standard deviation.
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levents reported symptoms resembling a transient ischaemic attack
4 days after starting thalidomide. Two patients developed acute
urinary retention after 10 and 17 weeks on study and were only
able to void following transurethral resection of the prostate.
Screening NCS was undertaken in 13 patients, nine of whom
were identified as having an axonal sensory neuropathy compared
with reference values for people over the age of 60 (Po0.01,
Figure 3A). One of these patients was a noninsulin dependent
diabetic, but none of the others had an associated comorbidity or
other recognised risk factor for nerve conduction deficit. None of
the seven men who completed the study exhibited a symptomatic
peripheral neuropathy on clinical examination at screening, but
four had an axonal sensory neuropathy on NCS. At the end of the
trial, all patients remained clinically asymptomatic on neurological
examination, but the average of the sensory potentials showed a
significant reduction, such that all seven men had an axonal
sensory neuropathy (P¼0.01, Figure 3B).
No patient with normal renal function at screening subsequently
showed impairment of serum urea and electrolytes. One patient
with pre-existing chronic renal failure and another with renal
insufficiency because of ureteric obstruction showed further
deterioration in renal function. Haematological toxicity did not
occur in any patient, including one with pernicious anaemia and
another with Hodgkin’s disease and sarcoidosis. There was no
deterioration in liver function, including in a patient with severe
fatty change caused by alcoholic liver disease. One patient with
painful bony metastases received intravenous strontium 4 months
prior to the study and short-course external beam radiotherapy
with oral corticosteroids during the study; the addition of
corticosteroids did not adversely affect the clinical status of the
patient.
Quality of life
General functioning and quality of life were well maintained on
thalidomide, with no significant changes for the scores on
calculated scales of the SF 36 questionnaire (Table 5). Other than
the two cases of acute urinary retention documented above, there
was no significant change in lower urinary tract symptoms on the
ICS male questionnaire.
DISCUSSION
The current results indicate that low-dose thalidomide can
decrease PSA levels in just under 40% of patients with androgen-
independent prostate adenocarcinoma, suggesting the potential for
improved disease control. Six of the 16 patients for whom data
were available showed a fall in PSA after starting thalidomide,
which was sustained while taking the drug. Three of these
completed the full study period and developed a rising PSA
subsequently. A recent clinical trial of thalidomide for androgen-
independent prostate cancer randomised patients to a low-dose
arm of 200mg daily, or a high-dose arm, escalating to the highest
tolerated dose (up to 1200mg) (Figg et al, 2001). In all, 15% of
patients showed a PSA decline of over 50%, and 28% showed a
decline of at least 40%, all of whom were in the low-dose arm (Figg
et al, 2001). Higher doses appeared to result in loss of efficacy,
perhaps reflecting the known immunosuppressive effects of
thalidomide, which may facilitate disease progression. Our data
indicate that similar effects on serum PSA are seen at an even
lower dose (100mg daily), in that 15% of patients showed a PSA
decline of over 50%, with a reduced incidence of adverse effects.
PSA has been proposed as a tumour marker for prostate
adenocarcinoma, the levels providing an indication of disease
volume and biological activity, such that a fall in PSA indicates a
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Figure 3 Nerve conduction study findings. Nerve conduction studies
revealed a significant reduction in SNAP in men with androgen-
independent prostate cancer (n¼13) compared with reference values
for men over the age of 60 (A). A significant fall in SNAP occurred in seven
men receiving thalidomide 100mg daily for a 6-month period (B).
Table 4 Adverse drug effects
Adverse effect n Discontinued therapy
Constipation 9 0
Sedation hangover 3 1
Dizziness 2 1
Transient ischaemic attack 1 1
Clinical peripheral neuropathy 0 0
Dry skin 1 0
Rash 1 0
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lpotential beneficial effect (Kelly et al, 1993; Sartor et al, 1998).
However, it should be remembered that selection of disease
markers is a problem in clinical trials for metastatic prostate
cancer (Morris and Scher, 2002). As recommended by the
guidelines of the Prostate-Specific Antigen Working Group
(Bubley et al, 1999), a decline in serum PSA of at least 50%
without clinical evidence of progression was employed as the main
outcome measure in the current study. Nevertheless, although a
decline in PSA or PSA velocity suggests clinical benefit, it is still
debated how much of a decline is significant and its precise
implication, while radiological assessment of metastatic disease is
insensitive and difficult to interpret (Morris and Scher, 2002).
Thalidomide has been observed to increase PSA expression in a
prostate cancer cell line in vitro (Dixon et al, 1999), so the PSA
reduction observed in some patients probably reflects a differing
effect on tumours in vivo. We found a significant link between the
changes in PSA and circulating bFGF levels. Thalidomide is known
to reduce angiogenic activity through selective inhibition of bFGF
(D’Amato et al, 1994) and tumour-associated macrophages (Joseph
and Isaacs, 1998). Since angiogenesis is important in the
development and metastasis of solid tumours in general (Folkman,
1971) and it is a negative prognostic marker in prostate cancer
specifically (Eckhardt and Pluda, 1997), this may reflect the
mechanism by which thalidomide is acting in androgen-indepen-
dent prostate cancer.
Peripheral neuropathy is a recognised complication of thalido-
mide (Tseng et al, 1996), with older persons at greater risk
(Ochonisky et al, 1994). We demonstrated that nine out of 13
patients in this study, including four of the seven men who were on
treatment for 6 months, had a ‘para-neoplastic neuropathy’ at
screening, which has previously been reported in association with
prostate cancer (Lucchinetti et al, 1998). By the end of the study,
all patients tested had a sensory neuropathy on NCS, and would
have had to discontinue treatment on the basis of safety
recommendations in the presence of a 50% decrease in measured
parameters (Gardner-Medwin et al, 1994). While thalidomide is a
potential contributory factor, the para-neoplastic neuropathy seen
in the majority of screened patients may have emerged further
during the study period. Local pelvic plexus infiltration could also
explain the NCS findings, but would have to be symmetric and
widespread and no corroborating clinical features were detected
indicating this pathology. A high incidence of peripheral neuro-
pathy in androgen-independent prostate cancer has been reported
previously in a study that also recorded onset of symptomatic
peripheral neuropathy in six out of 67 patients receiving a daily
dose of at least 200mg (Molloy et al, 2001). In this study, six out of
eight men treated for 6 months and all three men treated for 9
months developed a neuropathy. The fact that no patient
developed symptoms in the current study argues in favour of
lower dose treatment, which requires close clinical supervision and
electrophysiological monitoring nevertheless. Future studies might
usefully address use of even lower doses.
Further reported adverse effects of thalidomide include con-
stipation, headache, nausea, weight gain, oedema, transient rashes
and somnolence (Tseng et al, 1996). These effects are generally
minor. Neither the SF 36 nor the ICS male questionnaire scores
showed any significant change in the current study. Scores on the
calculated SF 36 scales at screening were worse than values for
healthy men of equivalent age (Brazier et al, 1992; Ware et al,
1993), or men with benign prostatic hyperplasia and hypertension
(Ware et al, 1993). The catastrophic consequences of previous use
of thalidomide to treat morning sickness of pregnancy means its
use in current practice requires sensitive handling and precautions
to avoid women of child-bearing potential being exposed to the
drug. Thalidomide is unlicensed in the United Kingdom and only
available on a named-patient basis. It was granted FDA approval in
the USA in 1998, for use in cutaneous manifestations of leprosy,
under controls requiring counselling and detailed consent (Zeldis
et al, 1999).
The current results suggest that thalidomide at a dose of 100mg
daily influences the disease process in a subgroup of patients with
androgen-independent prostate cancer, although no predictor of
response has yet been identified. The side effect profile and the
possibility of response mean that thalidomide can legitimately be
discussed with patients who have failed other forms of therapy, but
the development of sensory changes on NCS requires careful
monitoring. Most angiogenesis-inhibiting agents are cytostatic and
theoretically could provide additional benefit in combination with
other chemotherapeutic agents, particularly where the overall
tumour burden is low (Figg et al, 2001). A reduction in serum PSA
of at least 50%, as seen in three men in the current study, may
predict a relatively prolonged survival (Kelly et al, 1993; Sartor
et al, 1998). Consequently, low-dose thalidomide may have
potential as an adjunct to hormonal manipulation and other
agents in therapy of poor prognosis or advanced prostate cancer,
although further work is required to identify those likely to benefit.
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